You are here: Industry Insights > NERLYNX

News List

Puma Biotechnology’s NERLYNX Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer FirstWordPharma
January 13, 2022
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment...
New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority En-CPhI.CN
December 03, 2019
A new breast cancer drug shown to significantly reduce the risk of cancer recurrence has received approval in Singapore – at least six months ahead of its expected schedule.
Knight Therapeutics licences cancer drug from Puma Biotechnology pharmaceutical-technology
January 15, 2019
Canada-based Knight Therapeutics signed an exclusive licence agreement with Puma Biotechnology to commercialise Nerlynx (neratinib) medicine in the country.....
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX (neratinib) in Canada firstwordpharma
January 13, 2019
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) i
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX (neratinib) in Canada firstwordpharma
January 13, 2019
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) i
After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term fiercepharma
June 25, 2018
Former Puma Biotechnology executive Robert Gadimian made millions during his time at the company, but after illegally trading on insider information, he has returned $1.1 million and been ordered to serve a prison term.
Specialised Therapeutics to commercialise Puma’s Nerlynx for breast cancer pharmaceutical-technology
November 28, 2017
Nerlynx is not yet approved for commercialization outside the United States.
Puma to price new cancer med Nerlynx at a higher-than-expected $10K per month: report biospectrumasia
July 21, 2017
Shares of Puma Biotechnology have tripled since the start of the year to more than $95, as the Los Angeles company gets set to launch its debut drug, Nerlynx (neratinib) for HER2-positive breast cancer.